Isoliquiritigenin inhibits the proliferation, migration and metastasis of Hep3B cells via suppressing cyclin D1 and PI3K/AKT pathway

The overall survival rate of patients with hepatocellular carcinoma (HCC) has remained unchanged over the last several decades. Therefore, novel drugs and therapies are required for HCC treatment. Isoliquiritigenin (ISL), a natural flavonoid predominantly isolated from the traditional Chinese medici...

Descripción completa

Detalles Bibliográficos
Autores principales: Huang, Yun, Liu, Chen, Zeng, Wu-Cha, Xu, Guo-Yan, Wu, Jian-Min, Li, Zhi-Wen, Huang, Xuan-Yu, Lin, Rong-Jin, Shi, Xi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Portland Press Ltd. 2020
Materias:
Cancer
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6944659/
https://www.ncbi.nlm.nih.gov/pubmed/31840737
http://dx.doi.org/10.1042/BSR20192727

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6944659/
https://www.ncbi.nlm.nih.gov/pubmed/31840737
http://dx.doi.org/10.1042/BSR20192727

Ejemplares similares